Ekso Bionics (NASDAQ:EKSO) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research note published on Sunday. The firm issued a hold rating on the stock.

Several other research firms have also recently commented on EKSO. HC Wainwright reissued a “buy” rating and set a $9.00 target price on shares of Ekso Bionics in a research note on Tuesday, January 14th. Lake Street Capital lowered their price objective on Ekso Bionics from $2.50 to $2.00 and set a “buy” rating for the company in a research report on Tuesday, October 29th.

Ekso Bionics Stock Performance

Shares of Ekso Bionics stock opened at $0.55 on Friday. The business has a 50-day moving average of $0.63 and a 200 day moving average of $0.84. Ekso Bionics has a 12 month low of $0.47 and a 12 month high of $2.16. The stock has a market capitalization of $12.01 million, a price-to-earnings ratio of -0.84 and a beta of 1.46. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.81 and a quick ratio of 2.14.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.